ArticleIndian journal of dermatology

An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria.

Abhishek De et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.